BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22285761)

  • 1. Crystal structure of the urokinase receptor in a ligand-free form.
    Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
    J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
    Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
    J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.
    Gårdsvoll H; Kjaergaard M; Jacobsen B; Kriegbaum MC; Huang M; Ploug M
    J Biol Chem; 2011 Dec; 286(50):43515-26. PubMed ID: 22025616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
    Liang OD; Chavakis T; Kanse SM; Preissner KT
    J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
    Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
    J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.
    Huai Q; Zhou A; Lin L; Mazar AP; Parry GC; Callahan J; Shaw DE; Furie B; Furie BC; Huang M
    Nat Struct Mol Biol; 2008 Apr; 15(4):422-3. PubMed ID: 18376415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
    Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
    Gårdsvoll H; Ploug M
    J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structures of the ligand-binding region of uPARAP: effect of calcium ion binding.
    Yuan C; Jürgensen HJ; Engelholm LH; Li R; Liu M; Jiang L; Luo Z; Behrendt N; Huang M
    Biochem J; 2016 Aug; 473(15):2359-68. PubMed ID: 27247422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
    Li Y; Lawrence DA; Zhang L
    J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization.
    Sidenius N; Andolfo A; Fesce R; Blasi F
    J Biol Chem; 2002 Aug; 277(31):27982-90. PubMed ID: 12034711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
    Hillig T; Engelholm LH; Ingvarsen S; Madsen DH; Gårdsvoll H; Larsen JK; Ploug M; Danø K; Kjøller L; Behrendt N
    J Biol Chem; 2008 May; 283(22):15217-23. PubMed ID: 18362146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
    Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
    Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
    Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner KT
    FEBS Lett; 1997 Dec; 420(1):79-85. PubMed ID: 9450554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
    Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
    J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells.
    Margheri F; Manetti M; Serratì S; Nosi D; Pucci M; Matucci-Cerinic M; Kahaleh B; Bazzichi L; Fibbi G; Ibba-Manneschi L; Del Rosso M
    Arthritis Rheum; 2006 Dec; 54(12):3926-38. PubMed ID: 17133606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
    Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
    EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of the unoccupied murine urokinase-type plasminogen activator receptor (uPAR) reveals a tightly packed DII-DIII unit.
    Liu M; Lin L; Høyer-Hansen G; Ploug M; Li H; Jiang L; Yuan C; Li J; Huang M
    FEBS Lett; 2019 Jun; 593(11):1236-1247. PubMed ID: 31044429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.